Positively selected modifications in the pore of TbAQP2 allow pentamidine to enter Trypanosoma brucei

  1. Ali Alghamdi
  2. Jane C Munday
  3. Gustavo Daniel Campagnaro
  4. Dominik Gurvic
  5. Fredrik Svensson
  6. Chinyere E Okpara
  7. Arvind Kumar
  8. Juan Quintana
  9. Maria Esther Martin Abril
  10. Patrik Milić
  11. Laura Watson
  12. Daniel Paape
  13. Luca Settimo
  14. Anna Dimitriou
  15. Joanna Wielinska
  16. Graeme Smart
  17. Laura F Anderson
  18. Christopher M Woodley
  19. Siu Pui Ying Kelly
  20. Hasan MS Ibrahim
  21. Fabian Hulpia
  22. Mohammed I Al-Salabi
  23. Anthonius A Eze
  24. Ibrahim A Teka
  25. Simon Gudin
  26. Mark Field
  27. Christophe Dardonville
  28. Richard R Tidwell
  29. Mark Carrington
  30. Paul O'Neill
  31. David W Boykin
  32. Ulrich Zachariae
  33. Harry P De Koning  Is a corresponding author
  1. University of Glasgow, United Kingdom
  2. University of Dundee, United Kingdom
  3. IOTA Pharmaceuticals Ltd, United Kingdom
  4. University of Liverpool, United Kingdom
  5. Georgia State University, United States
  6. University of Ghent, Belgium
  7. CSIC, Spain
  8. University of North Carolina at Chapel Hill, United States
  9. University of Cambridge, United Kingdom

Abstract

Mutations in the Trypanosoma brucei aquaporin AQP2 are associated with resistance to pentamidine and melarsoprol. We show that TbAQP2 but not TbAQP3 was positively selected for increased pore size from a common ancestor aquaporin. We demonstrate that TbAQP2's unique architecture permits pentamidine permeation through its central pore and show how specific mutations in highly conserved motifs affect drug permeation. Introduction of key TbAQP2 amino acids into TbAQP3 renders the latter permeable to pentamidine. Molecular dynamics demonstrates that permeation by dicationic pentamidine is energetically favourable in TbAQP2, driven by the membrane potential, although aquaporins are normally strictly impermeable for ionic species. We also identify the structural determinants that make pentamidine a permeant although most other diamidine drugs are excluded. Our results have wide-ranging implications for optimising antitrypanosomal drugs and averting cross-resistance. Moreover, these new insights in aquaporin permeation may allow the pharmacological exploitation of other members of this ubiquitous gene family.

Data availability

All data generated or analysed during this study are included in the manuscript and supporting files. Source data files have been provided that cover all figures and give raw data, averages, statistics etc.

Article and author information

Author details

  1. Ali Alghamdi

    Institute of Infection, Immunity and Inflammation, College of Medical, Veterinary and Life Sciences, University of Glasgow, Glasgow, United Kingdom
    Competing interests
    The authors declare that no competing interests exist.
  2. Jane C Munday

    Institute of Infection, Immunity and Inflammation, College of Medical, Veterinary and Life Sciences, University of Glasgow, Glasgow, United Kingdom
    Competing interests
    The authors declare that no competing interests exist.
  3. Gustavo Daniel Campagnaro

    Institute of Infection, Immunity and Inflammation, College of Medical, Veterinary and Life Sciences, University of Glasgow, Glasgow, United Kingdom
    Competing interests
    The authors declare that no competing interests exist.
    ORCID icon "This ORCID iD identifies the author of this article:" 0000-0001-6542-0485
  4. Dominik Gurvic

    2.Computational Biology Centre for Translational and Interdisciplinary Research, University of Dundee, Dundee, United Kingdom
    Competing interests
    The authors declare that no competing interests exist.
  5. Fredrik Svensson

    Chemoinformatics, IOTA Pharmaceuticals Ltd, Cambridge, United Kingdom
    Competing interests
    The authors declare that no competing interests exist.
  6. Chinyere E Okpara

    Department of Chemistry, University of Liverpool, Liverpool, United Kingdom
    Competing interests
    The authors declare that no competing interests exist.
  7. Arvind Kumar

    Chemistry Department, Georgia State University, Atalanta, United States
    Competing interests
    The authors declare that no competing interests exist.
  8. Juan Quintana

    School of Life Sciences, University of Dundee, Dundee, United Kingdom
    Competing interests
    The authors declare that no competing interests exist.
  9. Maria Esther Martin Abril

    Institute of Infection, Immunity and Inflammation, College of Medical, Veterinary and Life Sciences, University of Glasgow, Glasgow, United Kingdom
    Competing interests
    The authors declare that no competing interests exist.
  10. Patrik Milić

    Institute of Infection, Immunity and Inflammation, College of Medical, Veterinary and Life Sciences, University of Glasgow, Glasgow, United Kingdom
    Competing interests
    The authors declare that no competing interests exist.
  11. Laura Watson

    Institute of Infection, Immunity and Inflammation, College of Medical, Veterinary and Life Sciences, University of Glasgow, Glasgow, United Kingdom
    Competing interests
    The authors declare that no competing interests exist.
  12. Daniel Paape

    The Wellcome Trust Centre for Molecular Parasitology, Institute of Infection, Immunity and Inflammation,, University of Glasgow, Glasgow, United Kingdom
    Competing interests
    The authors declare that no competing interests exist.
  13. Luca Settimo

    Institute of Infection, Immunity and Inflammation, College of Medical, Veterinary and Life Sciences, University of Glasgow, Glasgow, United Kingdom
    Competing interests
    The authors declare that no competing interests exist.
  14. Anna Dimitriou

    Institute of Infection, Immunity and Inflammation, College of Medical, Veterinary and Life Sciences, University of Glasgow, Glasgow, United Kingdom
    Competing interests
    The authors declare that no competing interests exist.
  15. Joanna Wielinska

    Institute of Infection, Immunity and Inflammation, College of Medical, Veterinary and Life Sciences, University of Glasgow, Glasgow, United Kingdom
    Competing interests
    The authors declare that no competing interests exist.
  16. Graeme Smart

    Institute of Infection, Immunity and Inflammation, College of Medical, Veterinary and Life Sciences, University of Glasgow, Glasgow, United Kingdom
    Competing interests
    The authors declare that no competing interests exist.
  17. Laura F Anderson

    Institute of Infection, Immunity and Inflammation, College of Medical, Veterinary and Life Sciences, University of Glasgow, Glasgow, United Kingdom
    Competing interests
    The authors declare that no competing interests exist.
  18. Christopher M Woodley

    Department of Chemistry, University of Liverpool, Liverpool, United Kingdom
    Competing interests
    The authors declare that no competing interests exist.
  19. Siu Pui Ying Kelly

    Institute of Infection, Immunity and Inflammation, College of Medical, Veterinary and Life Sciences, University of Glasgow, Glasgow, United Kingdom
    Competing interests
    The authors declare that no competing interests exist.
  20. Hasan MS Ibrahim

    Institute of Infection, Immunity and Inflammation, College of Medical, Veterinary and Life Sciences, University of Glasgow, Glasgow, United Kingdom
    Competing interests
    The authors declare that no competing interests exist.
  21. Fabian Hulpia

    Laboratory for Medicinal Chemistry, University of Ghent, Ghent, Belgium
    Competing interests
    The authors declare that no competing interests exist.
    ORCID icon "This ORCID iD identifies the author of this article:" 0000-0002-7470-3484
  22. Mohammed I Al-Salabi

    Institute of Infection, Immunity and Inflammation, College of Medical, Veterinary and Life Sciences, University of Glasgow, Glasgow, United Kingdom
    Competing interests
    The authors declare that no competing interests exist.
  23. Anthonius A Eze

    Institute of Infection, Immunity and Inflammation, College of Medical, Veterinary and Life Sciences, University of Glasgow, Glasgow, United Kingdom
    Competing interests
    The authors declare that no competing interests exist.
    ORCID icon "This ORCID iD identifies the author of this article:" 0000-0002-4821-1689
  24. Ibrahim A Teka

    Institute of Infection, Immunity and Inflammation, College of Medical, Veterinary and Life Sciences, University of Glasgow, Glasgow, United Kingdom
    Competing interests
    The authors declare that no competing interests exist.
  25. Simon Gudin

    Institute of Infection, Immunity and Inflammation, College of Medical, Veterinary and Life Sciences, University of Glasgow, Glasgow, United Kingdom
    Competing interests
    The authors declare that no competing interests exist.
  26. Mark Field

    School of Life Sciences, University of Dundee, Dundee, United Kingdom
    Competing interests
    The authors declare that no competing interests exist.
  27. Christophe Dardonville

    Instituto de Química Médica, CSIC, Madrid, Spain
    Competing interests
    The authors declare that no competing interests exist.
  28. Richard R Tidwell

    Department of Pathology and Lab Medicine, University of North Carolina at Chapel Hill, Chapel Hill, United States
    Competing interests
    The authors declare that no competing interests exist.
  29. Mark Carrington

    Department of Biochemistry, University of Cambridge, Cambridge, United Kingdom
    Competing interests
    The authors declare that no competing interests exist.
    ORCID icon "This ORCID iD identifies the author of this article:" 0000-0002-6435-7266
  30. Paul O'Neill

    Department of Chemistry, University of Liverpool, Liverpool, United Kingdom
    Competing interests
    The authors declare that no competing interests exist.
  31. David W Boykin

    Chemistry Department, Georgia State University, Atalanta, United States
    Competing interests
    The authors declare that no competing interests exist.
  32. Ulrich Zachariae

    School of Life Sciences / School of Science and Engineering, University of Dundee, Dundee, United Kingdom
    Competing interests
    The authors declare that no competing interests exist.
  33. Harry P De Koning

    Institute of Infection, Immunity and Inflammation, College of Medical, Veterinary and Life Sciences, University of Glasgow, Glasgow, United Kingdom
    For correspondence
    Harry.De-Koning@glasgow.ac.uk
    Competing interests
    The authors declare that no competing interests exist.
    ORCID icon "This ORCID iD identifies the author of this article:" 0000-0002-9963-1827

Funding

Medical Research Council (84733)

  • Harry P De Koning

National Institutes of Health (GM111749)

  • David W Boykin

Medical Research Council (MR/R015791/1)

  • Harry P De Koning

Scottish Universities Physics Alliance

  • Ulrich Zachariae

Albaha University, Saudi Arabia

  • Ali Alghamdi

Science Without Borders, Brazil (206385/2014-5)

  • Gustavo Daniel Campagnaro

Wellcome (204697/Z/16/Z)

  • Mark Field

The funders had no role in study design, data collection and interpretation, or the decision to submit the work for publication.

Copyright

© 2020, Alghamdi et al.

This article is distributed under the terms of the Creative Commons Attribution License permitting unrestricted use and redistribution provided that the original author and source are credited.

Metrics

  • 1,671
    views
  • 224
    downloads
  • 26
    citations

Views, downloads and citations are aggregated across all versions of this paper published by eLife.

Download links

A two-part list of links to download the article, or parts of the article, in various formats.

Downloads (link to download the article as PDF)

Open citations (links to open the citations from this article in various online reference manager services)

Cite this article (links to download the citations from this article in formats compatible with various reference manager tools)

  1. Ali Alghamdi
  2. Jane C Munday
  3. Gustavo Daniel Campagnaro
  4. Dominik Gurvic
  5. Fredrik Svensson
  6. Chinyere E Okpara
  7. Arvind Kumar
  8. Juan Quintana
  9. Maria Esther Martin Abril
  10. Patrik Milić
  11. Laura Watson
  12. Daniel Paape
  13. Luca Settimo
  14. Anna Dimitriou
  15. Joanna Wielinska
  16. Graeme Smart
  17. Laura F Anderson
  18. Christopher M Woodley
  19. Siu Pui Ying Kelly
  20. Hasan MS Ibrahim
  21. Fabian Hulpia
  22. Mohammed I Al-Salabi
  23. Anthonius A Eze
  24. Ibrahim A Teka
  25. Simon Gudin
  26. Mark Field
  27. Christophe Dardonville
  28. Richard R Tidwell
  29. Mark Carrington
  30. Paul O'Neill
  31. David W Boykin
  32. Ulrich Zachariae
  33. Harry P De Koning
(2020)
Positively selected modifications in the pore of TbAQP2 allow pentamidine to enter Trypanosoma brucei
eLife 9:e56416.
https://doi.org/10.7554/eLife.56416

Share this article

https://doi.org/10.7554/eLife.56416

Further reading

    1. Biochemistry and Chemical Biology
    Jianheng Fox Liu, Ben R Hawley ... Samie R Jaffrey
    Tools and Resources

    N 6,2’-O-dimethyladenosine (m6Am) is a modified nucleotide located at the first transcribed position in mRNA and snRNA that is essential for diverse physiological processes. m6Am mapping methods assume each gene uses a single start nucleotide. However, gene transcription usually involves multiple start sites, generating numerous 5’ isoforms. Thus, gene-level annotations cannot capture the diversity of m6Am modification in the transcriptome. Here, we describe CROWN-seq, which simultaneously identifies transcription-start nucleotides and quantifies m6Am stoichiometry for each 5’ isoform that initiates with adenosine. Using CROWN-seq, we map the m6Am landscape in nine human cell lines. Our findings reveal that m6Am is nearly always a high stoichiometry modification, with only a small subset of cellular mRNAs showing lower m6Am stoichiometry. We find that m6Am is associated with increased transcript expression and provide evidence that m6Am may be linked to transcription initiation associated with specific promoter sequences and initiation mechanisms. These data suggest a potential new function for m6Am in influencing transcription.

    1. Biochemistry and Chemical Biology
    2. Microbiology and Infectious Disease
    Eva Herdering, Tristan Reif-Trauttmansdorff ... Ruth Anne Schmitz
    Research Article

    Glutamine synthetases (GS) are central enzymes essential for the nitrogen metabolism across all domains of life. Consequently, they have been extensively studied for more than half a century. Based on the ATP-dependent ammonium assimilation generating glutamine, GS expression and activity are strictly regulated in all organisms. In the methanogenic archaeon Methanosarcina mazei, it has been shown that the metabolite 2-oxoglutarate (2-OG) directly induces the GS activity. Besides, modulation of the activity by interaction with small proteins (GlnK1 and sP26) has been reported. Here, we show that the strong activation of M. mazei GS (GlnA1) by 2-OG is based on the 2-OG dependent dodecamer assembly of GlnA1 by using mass photometry (MP) and single particle cryo-electron microscopy (cryo-EM) analysis of purified strep-tagged GlnA1. The dodecamer assembly from dimers occurred without any detectable intermediate oligomeric state and was not affected in the presence of GlnK1. The 2.39 Å cryo-EM structure of the dodecameric complex in the presence of 12.5 mM 2-OG demonstrated that 2-OG is binding between two monomers. Thereby, 2-OG appears to induce the dodecameric assembly in a cooperative way. Furthermore, the active site is primed by an allosteric interaction cascade caused by 2-OG-binding towards an adaption of an open active state conformation. In the presence of additional glutamine, strong feedback inhibition of GS activity was observed. Since glutamine dependent disassembly of the dodecamer was excluded by MP, feedback inhibition most likely relies on the binding of glutamine to the catalytic site. Based on our findings, we propose that under nitrogen limitation the induction of M. mazei GS into a catalytically active dodecamer is not affected by GlnK1 and crucially depends on the presence of 2-OG.